ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE capsule, extended release

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

ASPIRIN (UNII: R16CO5Y76E) (ASPIRIN - UNII:R16CO5Y76E), DIPYRIDAMOLE (UNII: 64ALC7F90C) (DIPYRIDAMOLE - UNII:64ALC7F90C)

Pieejams no:

Golden State Medical Supply, Inc.

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Aspirin and Extended-Release Dipyridamole Capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and Extended-Release Dipyridamole Capsules are contraindicated in patients with known hypersensitivity to any of the product components. Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (NSAID) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema or bronchospasm. Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome. Risk Summary Available data from published studies and postmarketing experience with Aspirin and Extended-Release Dipyridamole Capsules use during pregnancy have not identified a clear association between Aspirin and Extended-Release Dipyridamole Capsules use and major birth defects, miscarriage, or adverse maternal or feta

Produktu pārskats:

Aspirin and Extended-Release Dipyridamole Capsules are available as a No. 00 capsule with Pink Opaque cap and Yellow Opaque body imprinted in black with “ Lannett ” and “330”, and filled with pellets and powder blend. Aspirin and Extended-Release Dipyridamole Capsules are supplied in unit-of-use bottles of 60 capsules (NDC 51407-271-60). Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Protect from excessive moisture.

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE- ASPIRIN AND EXTENDED-
RELEASE DIPYRIDAMOLE CAPSULE, EXTENDED RELEASE
GOLDEN STATE MEDICAL SUPPLY, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE CAPSULES.
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ASPIRIN AND EXTENDED-
RELEASE DIPYRIDAMOLE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION
FOR ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE CAPSULES.
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE CAPSULES, FOR ORAL USE
INITIAL U.S. APPROVAL: 1999
INDICATIONS AND USAGE
Aspirin and Extended-Release Dipyridamole Capsules are a combination
of aspirin and dipyridamole,
antiplatelet agents, indicated to reduce the risk of stroke in
patients who have had transient ischemia
of the brain or completed ischemic stroke due to thrombosis ( 1)
DOSAGE AND ADMINISTRATION
One capsule twice daily (morning and evening) with or without food (
2)
In case of intolerable headaches during initial treatment, switch to
one capsule at bedtime and low-
dose aspirin in the morning; resume BID dosing within one week ( 2.1)
Do not chew capsule ( 2)
Not interchangeable with the individual components of aspirin and
dipyridamole tablets ( 2)
Dispense in this unit-of-use container ( 16)
DOSAGE FORMS AND STRENGTHS
Capsule: 25 mg aspirin/200 mg extended-release dipyridamole ( 3)
CONTRAINDICATIONS
Hypersensitivity to any product ingredients ( 4.1)
Patients with known allergy to NSAIDs ( 4.2)
Patients with the syndrome of asthma, rhinitis, and nasal polyps (
4.2)
WARNINGS AND PRECAUTIONS
Aspirin and Extended-Release Dipyridamole Capsules increase the risk
of bleeding ( 5.1)
Avoid use in patients with severe hepatic or renal insufficiency (
5.2, 5.3)
Interrupt Aspirin and Extended-Release Dipyridamole Capsules 48 hours
before using intravenous
dipyridamole or other adenosinergic agents for stress testing ( 5.6,
7.1)
ADVERSE REACTIONS
The most frequently reported adverse reactions (>10% and greater than
placebo) were headache,
dyspepsi